Cartesian Therapeutics Announces Clinical Responses in First Cohort of Phase 1b/2a Trial in Myasthenia Gravis

Published on :

Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company pioneering RNA cell therapy in and beyond oncology, today announced clinical data from the first cohort of an ongoing Phase 1/2a clinical trial of Descartes-08 in patients with generalized Myasthenia Gravis (gMG). Descartes-08 is an mRNA-modified, autologous CAR T-cell product directed against B-Cell Maturation Antigen (BCMA).

Murat Kalayoglu, MD, PhD, President & CEO, Cartesian Therapeutics, Discusses New Frontline Therapy Treatment for Multiple Myeloma

Published on :

Murat Kalayoglu, MD, PhD, President & CEO, Cartesian Therapeutics, Discusses New Frontline Therapy Treatment for Multiple Myeloma Cartesian Therapeutics, a biopharmaceutical company that specializes in mRNA-engineered cell therapy, recently announced [….]

BioHealth Capital Region Showcases Strengths of Cutting Edge Therapies

Published on :

Biopharma and Life Science companies in the BioHealth Capital Region are known for their work with cutting edge technologies such as gene and cell therapies. Those strengths were on display at the 6th annual BioHealth Capital Region Forum.

21 Emerging Life Science Companies Fueling Maryland’s Biohealth Ecosystem

Published on :

Maryland is the epicenter of biotech and life science innovation in the BioHealth Capital Region (BHCR). The state is home to a burgeoning life science ecosystem, including a rapidly growing cell and gene therapy industry, a robust and growing advanced biomanufacturing environment, and a deep network of leading research universities and critical government life science research entities.